Excellence is just the beginning.


French German Italian Portuguese Russian

Leukemia Services — Clinical Trials

Childhood B-Lymphoblastic Leukemia Treatment Study

Risk-stratified randomized phase III testing of blinatumomab (IND# I17467, NSC# 765986) in first relapse of childhood B-lymphoblastic leukemia (B-ALL).

Chronic Lymphocytic Leukemia in Patients 70 Years of Age and Older Treatment Study

Ibrutinib and obinutuzumab with or without venetoclax in treating older patients with untreated chronic lymphocytic leukemia.

Chronic Lymphocytic Leukemia in Younger Patients Treatment Study

Ibrutinib and obinutuzumab with or without venetoclax in treating patients with chronic lymphocytic leukemia.

Clinical Study for Acute Myeloid Leukemia Patients with FLT3 Mutation

Clinical trial with combination therapies in AML with FLT3 mutation in patients not eligible for intensive induction chemotherapy.

Maintenance Study For Patients With Residual Myeloma Post-Transplant

Phase II randomized trial of continuation of post-transplant maintenance with single-agent lenalidomide vs. consolidation/maintenance with ixazomib-lenalidomide-dexamethasone in patients with residual myeloma.

Maintenance Therapy Study for Patients with FLT3/ITD Acute Myeloid Leukemia

Trial of gilteritinib administered as maintenance therapy following allogeneic transplant for patients with FLT3/ITD acute myeloid leukemia (AML).

Newly Diagnosed T-Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma Treatment Study

A phase Ill randomized trial investigating bortezomib (NSC #681239; IND #58443) on a modified augmented BFM (ABFM) backbone in newly diagnosed T-lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LLy).

Study of Transient Myeloproliferative Disorder in Children with Down Syndrome

Biology study of transient myeloproliferative disorder (TMD) in children with Down syndrome (DS).

Treatment Study for Newly Diagnosed High Risk B-Lymphoblastic Leukemia in Patients with Ph-like TKI Sensitive Mutations

A phase III randomized trial for newly diagnosed high risk B-lymphoblastic leukemia (B-ALL) including a stratum evaluating dasatinib (IND#73789, NSC#732517) in patients with Ph-like tyrosine kinase inhibitor (TKI) sensitive mutations.

Treatment Study for Patients with Acute Myeloid Leukemia

A phase III randomized trial for patients with de novo AML using bortezomib and sorafenib (IND# I14480, NSC# 681239, NSC# 724772) for patients with high allelic ratio FLT3/ITD.